422 related articles for article (PubMed ID: 9145718)
1. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
[TBL] [Abstract][Full Text] [Related]
2. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.
Carter HB; Epstein JI; Partin AW
Urology; 1999 Jan; 53(1):126-30. PubMed ID: 9886601
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
4. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
6. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
7. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
8. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
9. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
10. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
12. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
[TBL] [Abstract][Full Text] [Related]
13. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
14. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Kundu SD; Grubb RL; Roehl KA; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1116-20. PubMed ID: 15758718
[TBL] [Abstract][Full Text] [Related]
15. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less.
Noldus J; Stamey TA
J Urol; 1996 Feb; 155(2):441-3. PubMed ID: 8558630
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
19. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
20. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
